China Medicine Corporation (CHME) Research

China Medicine Corporation (CHME), founded in 2005 and headquartered in Guangzhou, China, is a pharmaceutical firm primarily engaged in the production and sale of a broad array of health products across China. Its extensive product line encompasses both conventional pharmaceuticals, including prescription and over-the-counter drugs, as well as traditional Chinese medicine (TCM) products, herbal remedies, and dietary supplements. The company further provides medical devices and custom medical formulations. These offerings target various health conditions, such as cancer and high blood pressure, alongside solutions for removing toxins from food and animal feeds. More specifically, their products address issues like poor heart circulation, chest pain, and headaches; respiratory and digestive infections (e.g., tonsillitis, gastroenteritis); liver and gallbladder diseases (e.g., hepatitis, cholecystitis); women's health concerns like irregular or painful menstruation; and general ailments such as anemia, fatigue, dizziness, and circulatory problems like cerebral arteriosclerosis and ischemic stroke. The company distributes its products nationwide via an established sales network within China. Initially incorporated as Lounsberry Holdings III, Inc., the company officially rebranded to China Medicine Corporation in May 2006.

Open China Medicine Corporation (CHME) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.